Role of the pharmacist in establishing lipid intervention programs

Pharmacotherapy

Volumn 23, Issue 9 II, 2003, Pages

  Ito, Matthew K ^a,b,c  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESEVELAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; EDUCATION PROGRAM; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LABORATORY DIAGNOSIS; PHARMACIST; PRACTICE GUIDELINE; REIMBURSEMENT; SKILL; SYMPTOMATOLOGY; TIME;

CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; PHARMACIES; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PRAVASTATIN; PROGRAM DEVELOPMENT; SIMVASTATIN; UNITED STATES;

EID: 0141791629     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.11.41S.32712     Document Type: Conference Paper

References (24)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
4. Fonarow GC, French WJ, Parsons LS, et al, for the National Registry of Myocardial Infarction 3 Participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
6. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
7. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Lancet 2002;360:7-22.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. AFCAPS/TexCAPS research group. JAMA 1998;279:1615-22.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
13. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001;6:129-35.
14. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-91.
15. Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to-simvastatin conversion on low-density lipoprotein cholesterol. Am J Health-Syst Pharm 2001;58:1734-9.
16. Farmer JA, Gotto AM Jr. Choosing the right lipid-regulating agent: a guide to selection. Drugs 1996;52:649-61.
17. Stein EA. An investigative look: selective cholesterol absorption inhibitor-embarking on a new standard of care. Am J Manag Care 2002;8(suppl 2):S36-9.
18. Hunninghake D, Insull WR, Toth P, Davidson D, Donovan JM, Durke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-16.
19. Olsson AG. Statin therapy and reduction in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am J Cardiol 2001;87(suppl):B33-6.
20. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
21. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
22. Ito MK, Stolley SN, Morreale AP, Lin JC, Marcus DB. Rationale, design, and baseline results of the pravastatin-to-simvastatin conversion lipid optimization program (PSCOP). Am J Health-Syst Pharm 1999;56:1107-13.
23. Fonarow GC, Gawlinski A. Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles. Am J Cardiol 2000;85:A10-17.
24. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001;87:819-22.